MindWalk Holdings Corp. (NASDAQ:HYFT) Receives Average Rating of “Hold” from Brokerages

MindWalk Holdings Corp. (NASDAQ:HYFT) has earned a consensus rating of “Hold” from the five ratings firms that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $5.00.

HYFT has been the topic of several research analyst reports. Wall Street Zen upgraded shares of MindWalk from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Zacks Research lowered shares of MindWalk from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of MindWalk in a report on Wednesday, July 15th. Finally, HC Wainwright restated a “buy” rating on shares of MindWalk in a research report on Monday, July 20th.

MindWalk Stock Performance

Shares of NASDAQ:HYFT opened at $1.41 on Wednesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.80 and a quick ratio of 2.72. MindWalk has a 1 year low of $0.99 and a 1 year high of $3.25. The company has a market cap of $65.86 million, a P/E ratio of -6.41 and a beta of 0.84. The stock’s fifty day moving average price is $1.44 and its 200-day moving average price is $1.37.

MindWalk (NASDAQ:HYFT) last released its quarterly earnings data on Wednesday, July 22nd. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). MindWalk had a negative return on equity of 92.61% and a negative net margin of 89.65%.The business had revenue of $3.03 million during the quarter. Sell-side analysts expect that MindWalk will post -0.21 earnings per share for the current year.

Institutional Investors Weigh In On MindWalk

Hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC lifted its holdings in shares of MindWalk by 8.4% during the 4th quarter. Renaissance Technologies LLC now owns 239,080 shares of the company’s stock valued at $435,000 after buying an additional 18,600 shares during the period. Bank of Montreal Can increased its position in MindWalk by 81.0% during the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock valued at $100,000 after acquiring an additional 24,500 shares during the last quarter. Virtu Financial LLC bought a new position in MindWalk in the fourth quarter valued at about $51,000. GSA Capital Partners LLP bought a new position in MindWalk in the second quarter valued at about $55,000. Finally, XTX Topco Ltd boosted its position in MindWalk by 118.6% in the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock worth $149,000 after purchasing an additional 44,331 shares during the last quarter. 6.70% of the stock is currently owned by hedge funds and other institutional investors.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.